(Q33500348)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301463%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

title

Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301463%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301463%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

author name string

P Comella

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301463%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

A Daponte

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301463%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

R Casaretti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301463%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

F Fiore

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301463%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

F Presutti

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301463%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

G Frasci

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301463%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

F Caponigro

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301463%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

A Gravina

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301463%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

A P Parziale

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301463%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

N Mozzillo

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301463%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

G Comella

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301463%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

publication date

1 July 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301463%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

6 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301463%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301463%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301463%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

page(s)

1326-1329

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301463%20AND%20SRC:MED&resulttype=core&format=json

Phase II study of interferon alpha-2a and dacarbazine in advanced melanoma.

6 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900120-2

7 January 2021

Interferon alpha-2a and dacarbazine in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900120-2

7 January 2021

Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900120-2

7 January 2021

Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900120-2

7 January 2021

Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900120-2

7 January 2021

Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900120-2

7 January 2021

Fotemustine plus dacarbazine for malignant melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900120-2

7 January 2021

Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma--an effective combination with unexpected toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900120-2

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900120-2

7 January 2021

Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900120-2

7 January 2021

10.1016/S0959-8049(97)00120-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9301463%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference